Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James B. Hoffman is active.

Publication


Featured researches published by James B. Hoffman.


Bioorganic & Medicinal Chemistry Letters | 2001

Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors

Kenneth J. Wilson; Carl R. Illig; Nalin Subasinghe; James B. Hoffman; M. Jonathan Rudolph; Richard Soll; Christopher J. Molloy; Roger F. Bone; David W. Green; Troy Randall; Marie Zhang; Frank Lewandowski; Zhao Zhou; Celia Sharp; Diane Maguire; Bruce L. Grasberger; Renee L. DesJarlais; John Spurlino

The serine protease urokinase (uPa) has been implicated in the progression of both breast and prostate cancer. Utilizing structure based design, the synthesis of a series of substituted 4-[2-amino-1,3-thiazolyl]-thiophene-2-carboxamidines is described. Further optimization of this series by substitution of the terminal amine yielded urokinase inhibitors with excellent activities.


Bioorganic & Medicinal Chemistry Letters | 2002

Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors.

M. Jonathan Rudolph; Carl R. Illig; Nalin Subasinghe; Kenneth J. Wilson; James B. Hoffman; Troy L. Randle; David W. Green; Chris Molloy; Richard Soll; Frank Lewandowski; Marie Zhang; Roger F. Bone; John Spurlino; Ingrid Deckman; Carl L. Manthey; Celia Sharp; Diane Maguire; Bruce L. Grasberger; Renee L. DesJarlais; Zhao Zhou

A study of the S1 binding of lead 5-methylthiothiophene amidine 3, an inhibitor of urokinase-type plasminogen activator, was undertaken by the introduction of a variety of substituents at the thiophene 5-position. The 5-alkyl substituted and unsubstituted thiophenes were prepared using organolithium chemistry. Heteroatom substituents were introduced at the 5-position using a novel displacement reaction of 5-methylsulfonylthiophenes and the corresponding oxygen or sulfur anions. Small alkyl group substitution at the 5-position provided inhibitors equipotent with but possessing improved solubility.


Bioorganic & Medicinal Chemistry Letters | 2001

Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors

Nalin Subasinghe; Carl R. Illig; James B. Hoffman; M. Jonathan Rudolph; Kenneth J. Wilson; Richard Soll; Troy L. Randle; David W. Green; Frank Lewandowski; Marie Zhang; Roger F. Bone; John Spurlino; Renee L. DesJarlais; Ingrid Deckman; Christopher J. Molloy; Carl L. Manthey; Zhau Zhou; Celia Sharp; Diane Maguire; Carl Crysler; Bruce L. Grasberger

The serine protease urokinase plasminogen activator (uPA) is thought to play a central role in tumor metastasis and angiogenesis. Molecular modeling studies suggest that 5-thiomethylthiopheneamidine inhibits uPA by binding at the S1 pocket of the active site. Further structure based elaboration of this residue resulted in a novel class of potent and selective inhibitors of uPA.


Bioorganic & Medicinal Chemistry Letters | 1995

Non-peptide oxytocin antagonists: identification and synthesis of a potent camphor aminosuccinimide

Doug W. Hobbs; Norman P. Gould; James B. Hoffman; Bradley V. Clineschmidt; Douglas J. Pettibone; Daniel F. Veber; Roger M. Freidinger

Abstract The structure activity relationships of a series of non-peptide oxytocin antagonists containing a camphor aminosuccinimide as a key structural element were investigated. A potent and selective analog was identified and prepared in diastereomerically pure form starting from aspartic acid.


Archive | 1999

Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors

Carl R. Illig; Nalin L. Subasinghe; James B. Hoffman; Kenneth J. Wilson; M. Jonathan Rudolph


Archive | 2001

Heteroaryl amidines, methylamidines and guanidines, and the use thereof as protease inhibitors

Carl R. Illig; Nalin L. Subasinghe; James B. Hoffman; Kenneth J. Wilson; M. Jonathan Rudolph; Juan J. Marugan


Archive | 2001

Compounds and compositions for treating C1s-mediated diseases and conditions

Carl R. Illig; Nalin L. Subasinghe; James B. Hoffman; Kenneth J. Wilson; M. Jonathan Rudolph; Roger F. Bone; Scott L. Klein; Troy L. Randle


Archive | 2002

Heteroaryl amidines, methylamidines and guanidines as protease inhibitors

Carl R. Illig; Nalin L. Subasinghe; James B. Hoffman; Kenneth J. Wilson; M. Jonathan Rudolph; Juan J. Marugan


Archive | 2000

Methods of treating C1s-mediated diseases and conditions and compositions thereof

Carl R. Illig; Nalin L. Subasinghe; James B. Hoffman; Kenneth J. Wilson; M. Jonathan Rudolph; Roger F. Bone; Scott L. Klein; Troy L. Randle


Archive | 1999

Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors

Carl R. Illig; Nalin L. Subasinghe; James B. Hoffman; Kenneth J. Wilson; M. Jonathan Rudolph; Juan J. Marugan

Collaboration


Dive into the James B. Hoffman's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Doug W. Hobbs

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Douglas J. Pettibone

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John Spurlino

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Juan J. Marugan

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge